Novel Agent Leads to Fibrosis Improvement in NASH

(MedPage Today) -- VIENNA – Treatment with an investigational FGF21 analogue improved fibrosis in patients with nonalcoholic steatohepatitis (NASH), according to a phase IIb trial. In the ENLIVEN study, patients with biopsy-confirmed NASH...
Source: MedPage Today Primary Care - Category: Primary Care Source Type: news
More News: Primary Care | Study